HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Conferences

Deyaa Adib, MD, on Safety Advantages of TAC T-Cell Therapy in Solid Tumors

September 26th 2022

The chief medical officer of Triumvira Immunologics discussed how TAC01-HER2 could address unmet needs in treating solid tumors.

Jeffrey Miller, MD, on Emerging Research With Natural Killer Cells

September 24th 2022

The deputy director of the Masonic Cancer Center discussed trends of presentations from ESMO 2022.

Deyaa Adib, MD, on Evaluating HER2 TAC T-Cell Therapy in Solid Tumors

September 22nd 2022

The chief medical officer of Triumvira Immunologics discussed updates from the TACTIC-2 study presented at ESMO Congress 2022.

Jeffrey Miller, MD, on Engaging NK Cells in Solid Tumors

September 20th 2022

The deputy director of the Masonic Cancer Center discussed the preclinical findings of his study on a TriKE engager and NK cells.

David S. Hong, MD, on the SURPASS Clinical Trial and TCR T-cell Therapy in Solid Tumors

September 19th 2022

Hong presented data from the SURPASS clinical trial at the 2022 European Society for Medical Oncology (ESMO) Congress.

Weijia Fang, MD, and Guoqiang Ai, MD, on the Future of IMC001 in Gastric and Colorectal Cancer

September 17th 2022

Fang commented on a limitation of the clinical trial pointed out at the European Society for Medical Oncology (ESMO) 2022 Congress.

Weijia Fang, MD, and Tianhang Luo, MD, on EpCAM-Targeted CAR-T Therapy in Advanced Colorectal and Gastric Cancer

September 13th 2022

Fang recently presented at the European Society for Medical Oncology (ESMO) 2022 Congress.

IL13Rα2 Universal CAR T Therapy Shows Antitumor Activity in Recurrent Glioma

September 11th 2022

MT026 had an overall response rate of 83.3% in a first-in-human, investigator-initiated trial.

SNK01/Checkpoint Inhibitor Combo Yields Sustained Remission in Advanced SRC Sarcoma Case

September 11th 2022

The FDA authorized the natural killer cell therapy combo for compassionate use.

Phase 1 Clinical Trial Will Assess CAR-T With Genetic and Epigenetic Reprogramming for Solid Tumors

September 11th 2022

Improved functional activity compared to ROR-1-targeted CAR-T therapies without the 2 forms of reprogramming was demonstrated in preclinical studies.